Vicore Pharma Holding AB (publ) (STO: VICO)

Market Cap	1.84B
Revenue (ttm)	104.24M
Net Income (ttm)	-200.06M
Shares Out	111.73M
EPS (ttm)	-1.80
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,818
Open	15.96
Previous Close	15.92
Day's Range	15.96 - 16.64
52-Week Range	12.36 - 24.10
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2024

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 24
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VICO